South Africa Orders Urgent Recall of Compounded Weight-Loss Drugs
Africa · Southern
Key Facts
—The recall. SAHPRA ordered a Class I, Type A recall of compounded semaglutide and tirzepatide products made by iDexis/Sentra Pharmacy.
—The warning. Prescribers and pharmacists face fines from R25,000 to R75,000 (about US$1,500–US$4,600) and potential loss of licence.
—The court case. Novo Nordisk won an interim High Court order barring iDexis from manufacturing or selling semaglutide-based medicines.
—The scale. iDexis was supplying around 84,500 units of compounded semaglutide products per month, more than combined Ozempic and Wegovy sales.
—The context. The crackdown sits inside a global battle over a weight-loss drug market projected to become a hundred-billion-dollar class.
South Africa’s health regulators have ordered an urgent nationwide recall of compounded weight-loss drugs and warned that healthcare professionals who continue prescribing or dispensing them face fines, disciplinary action and loss of licence.
What the recall covers
Three regulators — SAHPRA, the South African Pharmacy Council and the Health Professions Council of South Africa — issued a joint Class I, Type A recall, the highest alert level. It targets unregistered, compounded injectable products containing semaglutide and tirzepatide made by Pretoria-based iDexis/Sentra Pharmacy.
The recalled products include iDEXIS Semaglutide, iDEXIS Tirzepatide and hybrid formulations combining both compounds. These are copycat versions of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro.
Regulators said the products were manufactured with imported active pharmaceutical ingredients whose source and traceability could not be verified. Inspectors also found serious deficiencies in Good Manufacturing Practice, quality control and sterile-facility compliance.
The raid and the inspection findings
A joint inspection by SAHPRA and the Pharmacy Council at iDexis’s Pretoria facility around May 2026 found unlawful manufacture of unregistered GLP‑1 medicines for broad commercial distribution. Authorities concluded the operation went far beyond the tightly regulated compounding allowed for individual patients.
Officials raided the site, seized all GIP/GLP‑1 injectable products on the premises and ordered iDexis to initiate a full recall of affected stock already distributed through healthcare providers and pharmacies. The regulators cited a “severe risk to public health”.
Fines, discipline and licence revocation
SAPC CEO Vincent Tlala stated that pharmacists who continue distributing recalled iDexis products could face fines from R25,000 to R75,000 (about US$1,500–US$4,600). Where patients suffer harm, practitioners can be struck off the professional register after disciplinary hearings.
Regulators are working with the national health department’s director-general to revoke iDexis’s licence. They have also engaged law-enforcement authorities to act against those contravening medicines regulations.
Doctors, nurses and pharmacists who continue prescribing, dispensing or holding stock of the recalled compounded weight-loss drugs risk disciplinary action from all three regulatory bodies, including loss of their professional licence.
Novo Nordisk’s court victory against iDexis
The regulatory crackdown runs parallel to a High Court battle. The Gauteng Division in Pretoria granted Novo Nordisk South Africa an interim order barring iDexis and its director from manufacturing, supplying or marketing semaglutide-based medicines.
Court papers cited by Business Insider Africa revealed that iDexis was supplying around 84,500 units of compounded semaglutide products per month. That volume exceeded the combined South African sales of branded Ozempic and Wegovy.
iDexis has applied to appeal the judgment and has lodged separate appeals against SAHPRA and SAPC’s inspection findings. The company says independent testing it commissioned found no evidence of sterility breaches and that its products were safe.
A booming market meets an affordability gap
South Africa is experiencing surging demand for GLP‑1 weight-loss drugs, but registered products from Novo Nordisk and Eli Lilly remain prohibitively expensive for most households. That affordability gap has fuelled a grey market of cheaper, unregistered compounded versions sold through pharmacies, aesthetic clinics and online channels.
SAHPRA has warned consumers against buying weight-loss injections via unauthorised online platforms. GLP‑1 medicines have become the leading focus of the authority’s illicit-medicine investigations.
The iDexis recall sits at the intersection of public health, consumer inequality and corporate profit. Tightening regulation protects safety but also narrows low-cost options unless governments or insurers negotiate better pricing or support future generic pathways.
The global battle over compounded weight-loss drugs
Novo Nordisk’s South African action is part of a broader global strategy to clamp down on compounded versions of semaglutide that bypass regulatory approval and compete on price. In other jurisdictions, the Danish pharmaceutical giant has similarly targeted pharmacies and telehealth services offering cheaper alternatives.
The GLP‑1 boom has transformed Novo Nordisk and Eli Lilly into two of the world’s most valuable healthcare companies. Defending patents and market exclusivity in emerging markets like South Africa protects high-margin branded products and preserves pricing power.
For South Africa, the case exposes a structural dependency: African states rely on foreign originator companies for cutting-edge therapies. Robust enforcement protects public health but also reinforces global intellectual-property and pricing structures dominated by American and European firms, a dynamic explored in our pillar Africa: The New Scramble.
What happens next
SAHPRA has urged patients to return recalled products to their pharmacy or provider for reimbursement and to consult a healthcare professional for alternative treatment. The recall process is legally binding, and manufacturers must recover all affected stock from the market.
iDexis’s appeals against both the court order and the regulatory findings will be closely watched by the pharmaceutical industry. The outcome could shape how South Africa balances affordable access to weight-loss treatments against safety and regulatory compliance.
For global investors and pharmaceutical firms, the case signals that South Africa’s regulators are prepared to enforce standards firmly, even when that means restricting cheaper alternatives in a price-sensitive market.
Connected Coverage
More: South Africa news in English, every day from The Rio Times.
Frequently Asked Questions
What products are affected by the South African recall?
The recall covers compounded injectable products containing semaglutide and tirzepatide made by iDexis/Sentra Pharmacy, including iDEXIS Semaglutide, iDEXIS Tirzepatide and hybrid formulations combining both compounds. These are unregistered copycat versions of branded drugs such as Ozempic, Wegovy and Mounjaro.
What penalties do healthcare professionals face for prescribing recalled drugs?
Pharmacists who continue distributing recalled iDexis products face fines from R25,000 to R75,000 (about US$1,500–US$4,600). In cases where patients suffer harm, practitioners can be struck off the professional register. Doctors, nurses and pharmacists also risk disciplinary action from HPCSA, SAPC and SAHPRA, including loss of licence.
Why are compounded weight-loss drugs so popular in South Africa?
Registered GLP‑1 drugs from Novo Nordisk and Eli Lilly are prohibitively expensive for many South African households. This affordability gap has driven consumers toward cheaper compounded versions sold through pharmacies, aesthetic clinics and online channels, often without proper medical supervision or regulatory approval.
Sources
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.
Read More from The Rio Times